Revance Therapeutics, Inc.

NasdaqGM:RVNC Stok Raporu

Piyasa değeri: US$391.3m

Revance Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Revance Therapeutics CEO'su Mark Foley, Oct2019 tarihinde atandı, in görev süresi 5.08 yıldır. in toplam yıllık tazminatı $ 10.07M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.2% maaş ve 92.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.06% ine doğrudan sahiptir ve bu hisseler $ 4.13M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 5.4 yıldır.

Anahtar bilgiler

Mark Foley

İcra Kurulu Başkanı

US$10.1m

Toplam tazminat

CEO maaş yüzdesi7.2%
CEO görev süresi5.1yrs
CEO sahipliği1.1%
Yönetim ortalama görev süresi5.3yrs
Yönetim Kurulu ortalama görev süresi5.4yrs

Son yönetim güncellemeleri

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

Revance climbs 14% as FDA approves facial injectable for frown lines

Sep 08

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Aug 24

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Aug 04
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CEO Tazminat Analizi

Mark Foley'un ücretlendirmesi Revance Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$303m

Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$292m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Sep 30 2018n/an/a

-US$138m

Jun 30 2018n/an/a

-US$136m

Mar 31 2018n/an/a

-US$128m

Dec 31 2017US$338kn/a

-US$121m

Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 10.07M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.16M ).

Tazminat ve Kazançlar: Mark şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mark Foley (59 yo)

5.1yrs

Görev süresi

US$10,068,915

Tazminat

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mark Foley
CEO & Director5.1yrsUS$10.07m1.06%
$ 4.1m
Tobin Schilke
CFO & Principal Accounting Officer6yrsUS$3.97m0.092%
$ 361.8k
Dwight Moxie
Chief Legal Officer & General Counsel4.8yrsUS$3.53m0.046%
$ 178.3k
Jessica Serra
Head of Investor Relations & ESGno dataVeri yokVeri yok
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications7.9yrsVeri yokVeri yok
Taryn Conway
Vice President of Marketing5.6yrsVeri yokVeri yok
Amie Krause
Chief People Officer1.7yrsVeri yokVeri yok
Conor Gallagher
Head of Medical Affairs & Aesthetics6.5yrsVeri yokVeri yok
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead1.8yrsVeri yok0.10%
$ 391.4k
Erica Jordan
Chief Commercial Officerno dataVeri yok0.11%
$ 428.5k

5.3yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: RVNC 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Mark Foley
CEO & Director7.2yrsUS$10.07m1.06%
$ 4.1m
Angus Russell
Independent Chairman10.7yrsUS$346.03k0.049%
$ 192.1k
Jill Beraud
Independent Director5.4yrsUS$317.53k0.042%
$ 162.7k
Julian Gangolli
Independent Director8.3yrsUS$305.03k0.043%
$ 168.3k
Vladimir Coric
Independent Director1.7yrsUS$421.49k0.020%
$ 77.5k
Olivia Ware
Independent Director3.7yrsUS$295.03k0.030%
$ 118.1k
Carey Kolaja
Independent Director3.7yrsUS$304.18k0.030%
$ 117.7k
Christian Nolet
Independent Director5.3yrsUS$315.03k0.042%
$ 162.7k

5.4yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RVNC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).